Lpath Incorporated

Scott Pancoast - President & CEO

Background: From 1994 to 2004, Mr. Pancoast was managing partner of Western States Investment Corporation, a private San Diego venture capital fund with $30 million to $100 million under management depending on the time period. During that time, he was CEO or interim CEO for six start-up companies and served on the board of directors for over 15 companies, including three public companies. Prior to joining WSIC, he started and ran the Midwest division of a $300 million (in revenues) publicly traded company. He served as the Chairman/President of the San Diego Venture Group during the late 1990s. Mr. Pancoast earned a bachelors degree from the University of Virginia, and an M.B.A from the Harvard Business School.

Gary Atkinson - Sr. Vice President & Chief Financial Officer

Background: Mr. Atkinson has more than 20 years of financial management experience. Prior to joining Lpath, he served as the Chief Financial Officer for three private life science companies. In addition, Mr. Atkinson was the Vice President of Finance at Isis Pharmaceuticals, a publicly held pharmaceutical research and development company. He began his career with Ernst & Young, where he earned his CPA designation. Mr. Atkinson is a graduate of Brigham Young University.

Dario A. Paggiarino, M.D. - Sr. Vice President & Chief Development Officer

Background: Dr. Paggiarino brings to Lpath more than 25 years of experience in the pharmaceutical industry, having directed global development programs in a number of therapeutic areas including ophthalmology, pain, inflammatory conditions, and oncology. Most recently, Dr. Paggiarino served as Vice President and Therapeutic Unit Head for retina diseases at Alcon, a division of Novartis. He also served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases, and medical responsibilities for Macugen(R). Earlier in his career, he held R&D positions of increasing responsibility at Angelini Pharmaceuticals, a privately owned company, ultimately serving as president. Later he joined Pharmacia Global R&D where he was clinical program director of ophthalmology with responsibilities for Xalatan(R), the leading glaucoma therapy in the world, and ocular devices such as viscoelastics (Healon(R)) and intraocular lenses (CeeOn(R), Tecnis(R)). Dr. Paggiarino earned his degree in Medicine and General Surgery at the University of Rome La Sapienza and has authored numerous scientific articles.

Gary Woodnutt, Ph.D. - Sr. Vice President, Research

Background: Dr. Woodnutt brings to Lpath extensive experience in drug discovery and pharmaceutical research. Prior to joining Lpath, Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer/CovX, but his primary role at CovX, from 2006 to 2012, was as Vice President of Biology Research. From 2002 to 2006, Dr. Woodnutt was the Senior Vice President of Pharmaceutical Research and Development for Diversa Corporation. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he was employed for more than 20 years and rose to the position of Vice President and Head of Biology in the Antimicrobial and Host Defense Group. Dr. Woodnutt received his Ph.D. in biochemistry/physiology from the University of Reading, and he has authored numerous scientific articles.

Roger Sabbadini, Ph.D. - Vice President, Scientific Founder

Background: Dr. Sabbadini was a Professor of Biology for 32 years at San Diego State University and is currently a Professor Emeritus of Biology. He founded three biotechnology companies, including Lpath, that were incubated out of SDSU. Dr. Sabbadini has been interested in the role of bioactive lipids in  various diseases, including cancer, ocular disorders, neurotrauma, neuropathic pain, inflammation and heart disease. Dr. Sabbadini’s research focused on developing novel antibody-based therapeutics against bioactive lipids such as the sphingolipid, S1P  and these anti-S1P antibodies are now in Phase 2 clinical trials for ocular disorders and cancer. Dr. Sabbadini earned his Ph.D. at the University of California, Davis.

Leigh Hsu, Ph.D., M.B.A. - Vice President, Corporate Development

Background: Dr. Hsu has more than 13 years of business-development experience in the biotech industry. Prior to Lpath, he held positions of increasing responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics (which became a subsidiary of Schering AG, now Bayer). Dr. Hsu played a key role in Lpath's $517 million licensing deal with Pfizer for iSONEP™, and has extensive deal experience with organizations like Wyeth and GE Healthcare, as well as with several academic and research organizations, including the University of California, the University of Texas, Southwestern Medical Center and the Veterans Medical Research Foundation. He has published numerous scientific papers, primarily in the area of the molecular basis of neurodegenerative diseases. Dr. Hsu received his Ph.D. in Molecular Pathology from the University of California, San Diego, and his M.B.A. from the University of California, Irvine.

Glenn Stoller, M.D. - Head of Lpath Ocular

Background: Dr. Stoller is a practicing retinal-eye surgeon. He received his medical degree from NYU School of Medicine and performed his residency at the Harkness Eye Institute of Columbia Presbyterian Hospital. He completed his fellowship in medical and surgical diseases of the retina at New York Presbyterian Hospital—Cornell Campus in New York City. He has served as an advisor for a number of pharmaceutical companies. He is a former editorial board member of the American Academy of Ophthalmology and an active member of The Retina Society.